Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a vegf inhibitor
AssigneeGenentech, Inc.
InventorNicholas Choong
Life of this patent
Estimating the term…
Abstract
A combination therapy comprising a MEK inhibitor, a PD-1 axis inhibitor, and a VEGF inhibitor is provided for the treatment of colorectal cancer and metastatic colorectal cancer.
Claims30
A method of treating a subject having colorectal cancer, the method comprising administering to said subject a therapy comprising (i) a therapeutically effective amount of a MEK inhibitor, (ii) a therapeutically effective amount of a PD-1 axis inhibitor, and (iii) a therapeutically effective amount of a VEGF inhibitor.
A method of treating a subject having colorectal cancer, the method comprising administering to said subject a therapy comprising:
- (i) a therapeutically effective amount of cobimetinib or a pharmaceutically acceptable salt thereof;
- (ii) a therapeutically effective amount of a PD-L1 inhibitor that is an antibody comprising:
- (a) a heavy chain comprising HVR-H1 sequence of GFTFSDSWIH (SEQ ID NO:24), HVR-H2 sequence of AWISPYGGSTYYADSVKG (SEQ ID NO:25), and HVR-H3 sequence of RHWPGGFDY (SEQ ID NO:
- 12);
- and a light chain comprising HVR-L1 sequence of RASQDVSTAVA (SEQ ID NO:26), HVR-L2 sequence of SASFLYS (SEQ ID NO:27), and HVR-L3 sequence of QQYLYHPAT (SEQ ID NO:28), or
- (b) a heavy chain variable region comprising the amino acid sequence of EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWV AWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYC ARRHWPGGFDYWGQGTLVTVSS (SEQ ID NO:7) and a light chain variable region comprising the amino acid sequence of DIQMTQSPSS LSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIY SASFLY SGVP SRF SGSGSGTDFTLTIS SLQPEDFATYYCQQYLYHPATFGQGTK VEIKR (SEQ ID NO:9);
- and
- (iii) a therapeutically effective amount of a VEGF inhibitor that is an antibody comprising:
- (a) a heavy chain comprising HVR-H1 sequence of GYTFTNYGMN (SEQ ID NO:35), HVR-H2 sequence of WINTYTGEPTYAADFKR (SEQ ID NO:36), and HVR-H3 sequence of YPHYYGSSHWYFDV (SEQ ID NO:37);
- and a light chain comprising HVR-L1 sequence of SASQDISNYLN (SEQ ID NO:38), HVR-L2 sequence of FTSSLHS (SEQ ID NO:39), and HVR-L3 sequence of QQYSTVPWT (SEQ ID NO:40), or
- (b) a heavy chain variable region comprising the amino acid sequence of EVQLVESGGG LVQPGGSLRL SCAASGYTFT NYGMNWVRQA PGKGLEWVGW INTYTGEPTY AADFKRRFTF SLDTSKSTAY LQMNSLRAED TAVYYCAKYP HYYGSSHWYF DVWGQGTLVT VSS (SEQ ID NO:33) and a light chain variable region comprising the amino acid sequence of DIQMTQSPSS LSASVGDRVT ITCSASQDIS NYLNWYQQKP GKAPKVLIYF TSSLHSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YSTVPWTFGQ GTKVEIKR. (SEQ ID NO:34).
A kit for treating colorectal cancer in a human subject, the kit comprising a MEK inhibitor, a PD-1 axis inhibitor, a VEGF inhibitor and a package insert comprising instructions for using a therapeutically effective amount of the MEK inhibitor, a therapeutically effective amount of the PD-1 axis inhibitor and a therapeutically effective amount of the VEGF inhibitor for treating the subject.
A colorectal cancer therapy drug combination comprising:
- (i) a MEK inhibitor in a dose of from about 20 mg to about 100 mg;
- (ii) a PD-1 axis inhibitor in a dose of from about 400 mg to about 1200 mg;
- and
- (iii) a VEGF inhibitor in a dose of from about 5 mg/kg to about 15 mg/kg.
Dependencies are inferred from the claim text.